Brain tumor

Brain Cancer Canada Awards $80,000 towards Adolescent and Young Adult (AYA) Brain Cancer Research

Retrieved on: 
onsdag, maj 29, 2024
Patient, Prognosis, Brain tumor, Brain, Diagnosis, Sunnybrook Research Institute, Ageing, Neoplasm, Research, BCC, Medicine, AYA, Ayas, Personalized medicine, Medical imaging

Dr. Lim-Fat’s research addresses this critical issue by establishing a national network to improve outcomes for AYA brain tumor patients through precision medicine.

Key Points: 
  • Dr. Lim-Fat’s research addresses this critical issue by establishing a national network to improve outcomes for AYA brain tumor patients through precision medicine.
  • Brain Cancer Canada acknowledges the immense contributions of grassroots initiatives that have made these grants possible, including Farands for The Fight, Ride for Don, Run for Jayne, Chase’s Forest, Buckets for Brain Cancer, Burpees for Brain Cancer, Pat’s Head & Hearts, and Dr. Surya’s Charity Raffle.
  • This announcement follows three previous grants awarded earlier this month to support pioneering brain cancer research.
  • For more details about this groundbreaking research initiative and other efforts by Brain Cancer Canada, please contact [email protected]

May is Brain Cancer Awareness Month

Retrieved on: 
onsdag, maj 29, 2024
Oncology, Health, Other Health, Clinical Trials, Research, Science, Biotechnology, CE, Patient, Machine learning, Brain tumor, NHS Scotland, Diagnosis, Government, Liquid biopsy, Scottish, General practitioner, The Brain Tumour Charity, Cancer, EMBRACE, Brain, Artificial intelligence, NHS, Quality of life, Medical imaging

The Dxcover® Brain Cancer Liquid Biopsy is a simple blood test combined with artificial intelligence that can rapidly fast-track patients suspected to have a brain tumor for further treatment.

Key Points: 
  • The Dxcover® Brain Cancer Liquid Biopsy is a simple blood test combined with artificial intelligence that can rapidly fast-track patients suspected to have a brain tumor for further treatment.
  • This important project led by The Brain Tumour Charity (UK) and Dxcover occurred in February to ensure that policymakers understand the barriers to brain tumor diagnosis and the need to improve current diagnostic pathways.
  • Professor Baker also served on an expert roundtable discussion on May 14th in Westminster, London hosted by the Tessa Jowell Brain Cancer Mission .
  • The event gathered brain cancer industry and patient advocates to tackle crucial challenges in brain cancer research and discuss new UK government initiatives to accelerate progress in treatments and patient care for all ages.

Brain Cancer Canada Awards an $80,000 research grant to the development of dual function therapies that harness the body's own immune system to kill brain tumour cells in glioblastomas

Retrieved on: 
torsdag, maj 23, 2024
GBM, Lawson Health Research Institute, Patient, Doctor of Philosophy, DNA, Glioblastoma, University, Immune system, Diagnosis, FEN1, London Health Sciences Centre, BC Cancer Agency, Brain tumor, Neoplasm, Odyssey Re, Research, Cancer, Brain, Associate, Quality of life, Medical imaging

Dr. Stirling's project, titled "Developing new dual function therapies that kill tumour cells and activate immune responses in glioblastomas," targets the aggressive and notoriously treatment-resistant glioblastoma (GBM) tumors.

Key Points: 
  • Dr. Stirling's project, titled "Developing new dual function therapies that kill tumour cells and activate immune responses in glioblastomas," targets the aggressive and notoriously treatment-resistant glioblastoma (GBM) tumors.
  • The research focuses on a novel chemotherapeutic approach that not only targets tumor cells but also activates the local immune system, potentially overcoming the immune resistance often seen in glioblastomas.
  • Each of these grants is part of Brain Cancer Canada's broader initiative during May's Brain Cancer Awareness Month, known as 'Go Grey in May.'
  • These efforts collectively demonstrate our commitment to advancing research and support for brain cancer patients across Canada.

Brain Cancer Canada Awards Grant for Innovative Medical Avatar Technology to Improve Treatments in High Grade Gliomas like Glioblastoma

Retrieved on: 
torsdag, maj 16, 2024
Patient, Doctor of Philosophy, Survival, Faculty, Glioma, Neoplasm, Brain tumor, Research, Chorioallantoic membrane, Brain, FMSS, Chicken, CAM, Medical imaging

High grade gliomas can spread rapidly through brain tissue which typically leads to very poor prognosis for patients.

Key Points: 
  • High grade gliomas can spread rapidly through brain tissue which typically leads to very poor prognosis for patients.
  • The grant supports the innovative Sherbrooke Brain Cancer Avatar Initiative, employing novel CAMavatar technology.
  • This funding is part of Brain Cancer Canada's broader initiative during May's Brain Cancer Awareness Month, known as "Go Grey in May."
  • This is the second of four major grants issued by Brain Cancer Canada this month, highlighting its commitment to advancing research and support for brain cancer patients.

NeuroVigil, World’s Most Valuable Neurotech, Launches iBrain™ in US

Retrieved on: 
fredag, april 5, 2024
Head, Roche, MIT Technology Review, IP, FCCP, Clinic, Seed, Consciousness, Partnership, Novartis, SAN, DNA, Aneurysm, Critical care, Stanford School, Cedars-Sinai Medical Center, Lawyer, Harvard Medical School, DSS, University, MD, Hospital, FDA, Apnea, Brain, ALS, MIT, Neocortex, Biomarker, Bird, Doctor of Philosophy, Human, Brain tumor, BCIS, Silicon, Patent, VCS, Division

The investigators will initially not be allowed to modify anyone’s therapy based on iBrain data.

Key Points: 
  • The investigators will initially not be allowed to modify anyone’s therapy based on iBrain data.
  • A joint abstract by Dr. Low and Dr. Hawking featuring Dr. Hawking’s brain patterns analyzed by NeuroVigil’s technology was released as early as 2012.
  • The technology was also successfully demonstrated on ALS sufferer Augie Nieto in 2013 who spelled “COMMUNICATE” with his mind.
  • In the past two years, NeuroVigil has recruited talent from Amgen, Roche, Novartis and MIT in preparation for the launch.

CORRECTION -- NeuroVigil, World’s Most Valuable Neurotech Company, Launches in US

Retrieved on: 
fredag, april 5, 2024
Head, Roche, MIT Technology Review, IP, FCCP, Clinic, Seed, Consciousness, Partnership, Novartis, SAN, DNA, Aneurysm, Critical care, Stanford School, Cedars-Sinai Medical Center, Lawyer, Harvard Medical School, DSS, University, MD, Hospital, FDA, Apnea, Brain, ALS, MIT, Neocortex, Biomarker, Bird, Doctor of Philosophy, Human, Brain tumor, BCIS, Patent, VCS, Division

“Who needs implants when you have the real deal?” said Dr. Philip Low, PhD, NeuroVigil’s Chairman, Chief Executive and Technology Officer, Founder and Supermajority Owner.

Key Points: 
  • “Who needs implants when you have the real deal?” said Dr. Philip Low, PhD, NeuroVigil’s Chairman, Chief Executive and Technology Officer, Founder and Supermajority Owner.
  • The investigators will initially not be allowed to modify anyone’s therapy based on iBrain data.
  • The technology was also successfully demonstrated on ALS sufferer Augie Nieto in 2013 who spelled “COMMUNICATE” with his mind.
  • In the past two years, NeuroVigil has recruited talent from Amgen, Roche, Novartis and MIT in preparation for the launch.

NeuroVigil, World’s Most Valuable Neurotech Company, Launches in US

Retrieved on: 
fredag, april 5, 2024
Head, Roche, MIT Technology Review, IP, FCCP, Clinic, Seed, Consciousness, Partnership, Novartis, SAN, DNA, Aneurysm, Critical care, Stanford School, Cedars-Sinai Medical Center, Lawyer, Harvard Medical School, DSS, University, MD, Hospital, FDA, Apnea, Brain, ALS, MIT, Neocortex, Biomarker, Bird, Doctor of Philosophy, Human, Brain tumor, BCIS, Silicon, Patent, VCS, Division

The investigators will initially not be allowed to modify anyone’s therapy based on iBrain data.

Key Points: 
  • The investigators will initially not be allowed to modify anyone’s therapy based on iBrain data.
  • A joint abstract by Dr. Low and Dr. Hawking featuring Dr. Hawking’s brain patterns analyzed by NeuroVigil’s technology was released as early as 2012.
  • The technology was also successfully demonstrated on ALS sufferer Augie Nieto in 2013 who spelled “COMMUNICATE” with his mind.
  • In the past two years, NeuroVigil has recruited talent from Amgen, Roche, Novartis and MIT in preparation for the launch.

Dxcover Announces Three New Clinical Trials for Brain, Colorectal and Lung Cancer Detection

Retrieved on: 
tisdag, januari 9, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Other Health, Brain, FTIR, CREATE, Patient, Fourier, European Innovation Council, IVD, Cancer, Algorithm, Colonoscopy, Brain tumor, Disease, NHS, Machine learning, NHS Lothian, Colorectal cancer, EMBRACE, Medical imaging

Dxcover Limited , a clinical-stage diagnostics company pioneering multi-omic spectral analysis (MOSA) for early detection of multiple cancers, today announced it is initiating three pivotal clinical trials measuring efficacy of the company’s liquid biopsy technology for the detection of brain, colorectal and lung cancer.

Key Points: 
  • Dxcover Limited , a clinical-stage diagnostics company pioneering multi-omic spectral analysis (MOSA) for early detection of multiple cancers, today announced it is initiating three pivotal clinical trials measuring efficacy of the company’s liquid biopsy technology for the detection of brain, colorectal and lung cancer.
  • The company has launched its EMBRACE study, a 2,200-patient trial focused on the early detection of brain cancer.
  • Dxcover® Brain Cancer is a qualitative in vitro diagnostic (IVD) test analyzing blood serum by infrared spectroscopy to detect the signals indicative of brain cancer.
  • The Dxcover Brain Cancer test has been developed over four years with clinical support from NHS Lothian.

Calidi Biotherapeutics Announces Presentation of Clinical Study for NeuroNova with Recurrent High Grade Glioma at the 8th Oncolytic Virotherapy Summit

Retrieved on: 
onsdag, december 13, 2023
Biotechnology, Pharmaceutical, Oncology, General Health, Health, Infectious Diseases, Hospitals, Clinical Trials, NSC, B cell, M.D, Research, Safety, NYSE, Immune system, City, Northwestern University, HGG, Clinical trial, IND, SNV, Brain tumor, Northwest Biotherapeutics, Supernova, Patient, Tumor microenvironment, Medicine, Neoplasm, University, Virus, NNV, Pharmaceutical industry, Vaccine, Boston

“Our cell-based virotherapeutics are designed to target tumors directly and to help the immune system recognize and attack distant tumor sites,” said Boris R. Minev.

Key Points: 
  • “Our cell-based virotherapeutics are designed to target tumors directly and to help the immune system recognize and attack distant tumor sites,” said Boris R. Minev.
  • Updates to be presented at the upcoming 8th Oncolytic Virotherapy Summit include:
    Progress in Recurrent High Grade Glioma (HGG) Trial.
  • Calidi plans to commence a Phase 1b/2 clinical trial for NeuroNova (NNV1) in collaboration with Northwestern University during the first half of 2024.
  • The company’s research is focused on engineered oncolytic vaccinia virus to increase the tumor specificity and oncolytic potency with improved systemic anti-tumor immunity.

Brain Cancer Market: Drug Insights, Epidemiology Study, Clinical Trial Assessment, Pharma Consulting, and Regulatory Consulting | Disease Landscape Insights

Retrieved on: 
torsdag, oktober 12, 2023
Brain tumor, Neoplasm, Health, Health care, Drug development, Vomiting, Weight loss, Organization, Mortality, Scan, Disease, Nausea, Headache, Patient, EEG, Brain, Radiation exposure, Fatigue, Seizure, Clinical trial, Immune system, Genetic testing, DLI, Research, Risk, Medical imaging

Discover More About Pricing and Reimbursement, Epidemiology Study, and Healthcare @

Key Points: 
  • Discover More About Pricing and Reimbursement, Epidemiology Study, and Healthcare @
    Disease Landscape Insights has been offering healthcare consulting services to the Brain Cancer Market players operating in this vertical.
  • It has been assisting in treatment gaps identification, drug development, clinical trial feasibility analysis, and overall clinical trial management.
  • By providing comprehensive data analysis and strategic guidance, they empower brain cancer players to navigate the complex clinical trial landscape effectively.
  • Through their insights and tailored solutions, Disease Landscape Insights contributes significantly to the advancement of brain cancer therapies, ultimately fostering innovation and improved outcomes for patients battling this devastating disease.